⌘K

/Equities/XLON/DEST/RNS

Presenting at HC Wainwright Investment Conference

RNS Number : 5119Y

Destiny Pharma PLC

07 September 2022

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Destiny Pharma CEO, Neil Clark, to present

at the HC Wainwright 24^th Annual Global Investment Conference

Brighton, United Kingdom - 7 September 2022 - Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, today announces that Destiny Pharma's CEO, Neil Clark, will present virtually at the upcoming HC Wainwright 24^th Annual Global Investment Conference, being held on 12-14 September 2022 in New York and virtually.

The presentation will be available to view on demand from 1200 BST / 0700 ET on Monday 12 September 2022. To join the conference virtually, view the presentation and ask any questions, please click on the link above to register.

Presentation Title: Destiny Pharma Company Presentation

Presenter: Neil Clark

If you would like to meet with Destiny Pharma, please email us at [email protected] or contact us through the HC Wainwright conference meeting system if you are registered.

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
[email protected]

Optimum Strategic Communications
Mary Clark / Manel Mateus
+44 (0) 208 078 4357
[email protected]

MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12

Stern IR - US

Lilian Stern / Janhavi Mohite

+1-212-362-1200

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information on the company, please visit https://www.destinypharma.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAMZGGLRVVGZZM

Presenting at HC Wainwright Investment Conference - Destiny Pharma plc | RNS | Ticker